— Know what they know.
Not Investment Advice
Also trades as: HIK.L (LSE) · $vol 19M · HKMPY (OTC) · $vol 0M

HKMPF OTC

Hikma Pharmaceuticals PLC
1W: +0.0% 1M: -0.4% 3M: +15.0% YTD: +6.0% 1Y: -5.2% 3Y: -12.2% 5Y: -27.1%
$19.07
-3.12 (-14.05%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 62 · $4.6B mcap · 136M float · 0.0002% daily turnover · Short 86% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$4.6B
52W Range16.3425-25.34
Volume40
Avg Volume212
Beta0.65
Dividend$0.86
Analyst Ratings
1 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOSaid Samih Taleb Darwazah
Employees9,400
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2012-08-22
Websitehikma.com
10 Portman Square
London, GL W1H 6AZ
GB
44 20 7399 2760
About Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC is a global pharmaceutical firm engaged in the development, manufacturing, commercialization, and distribution of a wide array of medications, including its own branded products, licensed drugs, and generic formulations. These pharmaceutical offerings come in various forms, such as solids, semi-solids, liquids, and injectables. The company's operations are divided into three core segments: Injectables, which primarily supplies generic injectable medications to hospitals; Generics, focusing on oral and other non-injectable generic drugs for the retail market; and Branded, which provides both proprietary generics and in-licensed pharmaceuticals to retail consumers and healthcare institutions. Hikma's product portfolio addresses a broad spectrum of medical needs, spanning anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory disorders. Founded in 1978 and based in London, United Kingdom, the company extends its reach across the UK, the United States, the Middle East, North Africa, Europe, and other international markets.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms